Key facts
- This page summarizes Marc Stapley's Form 4 filing for VERACYTE, INC. (VCYT).
- 4 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Jun 2026, 21:38.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Tax liability
Options Exercise
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale.
Footnote F2
Due to an administrative error, shares of common stock acquired by the Reporting Person under the Veracyte, Inc. Employee Stock Purchase Plan on July 31, 2025 were incorrectly reported as 529 shares of common stock instead of 382 shares of common stock in a Form 4 filed on September 4, 2025, and these shares were overreported in subsequent Forms 4 filed by the Reporting Person. This column reflects the corrected balance.
Footnote F3
The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 24, 2025.
Footnote F4
Represents weighted average sales price. Sale prices for the transactions range from $50.00 to $50.52. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Footnote F5
The option is fully vested.